Promoter and lineage independent anti-silencing activity of the A2 ubiquitous chromatin opening element for optimized human pluripotent stem cell-based gene therapy

Biomaterials

Volumn 35, Issue 5, 2014, Pages 1531-1542

  Ackermann, Mania ^a   Lachmann, Nico ^a   Hartung, Susann ^a   Eggenschwiler, Reto ^a   Pfaff, Nils ^a   Happle, Christine ^a   Mucci, Adele ^a   Göhring, Gudrun ^a   Niemann, Heiner ^b   Hansen, Gesine ^a   Schambach, Axel ^a,c   Cantz, Tobias ^a   Zweigerdt, Robert ^a   Moritz, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Epigenetic silencing; Gene therapy; Lentiviral vector; Pluripotent stem cells; UCOE

Indexed keywords

ALKYLATION; CELL CULTURE; GENE THERAPY;

CLINICAL APPLICATION; EPIGENETIC SILENCING; ITS APPLICATIONS; LENTIVIRAL VECTOR; PLURIPOTENT STEM CELLS; TRANSGENE EXPRESSION; UCOE; VIRAL PROMOTERS;

STEM CELLS;

CD34 ANTIGEN; CYTARABINE; CYTIDINE DEAMINASE; GRANULOCYTE COLONY STIMULATING FACTOR; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

A2 UBIQUITOUS CHROMATIN OPENING ELEMENT; ANIMAL CELL; ANTI SILENCING ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CELL SELECTION; CLINICAL EFFECTIVENESS; CLONOGENIC ASSAY; DNA METHYLATION; DNA STRUCTURE; ECTODERM; EMBRYONIC STEM CELL; ENHANCER REGION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HEART MUSCLE CELL; HEMATOPOIETIC STEM CELL; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; LIVER CELL; MACROPHAGE; MESODERM; MONOCYTE; NONHUMAN; ONCOGENE C MYC; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SPLEEN FOCUS FORMING VIRUS; STEM CELL GENE THERAPY; TRANSGENE; WESTERN BLOTTING;

IPS; MURINAE;

EPIGENETIC SILENCING; GENE THERAPY; LENTIVIRAL VECTOR; PLURIPOTENT STEM CELLS; UCOE;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CHROMATIN; GENE SILENCING; GENETIC THERAPY; HEK293 CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSGENES;

EID: 84890141894     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.024     Document Type: Article

References (57)

1. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
2. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
3. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
4. Cherry A.B., Daley G.Q. Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med 2013, 64:277-290.
5. Sancho-Martinez I., Li M., Izpisua Belmonte J.C. Disease correction the iPSC way: advances in iPSC-based therapy. Clin Pharmacol Ther 2011, 89:746-749.
6. Schambach A., Cantz T., Baum C., Cathomen T. Generation and genetic modification of induced pluripotent stem cells. Expert Opin Biol Ther 2010, 10:1089-1103.
7. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005, 16:1241-1246.
8. Mukherjee S., Santilli G., Blundell M.P., Navarro S., Bueren J.A., Thrasher A.J. Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells. PLoS One 2011, 6:e17565.
9. Raya A., Rodriguez-Piza I., Guenechea G., Vassena R., Navarro S., Barrero M.J., et al. Disease-corrected haematopoietic progenitors from fanconi anaemia induced pluripotent stem cells. Nature 2009, 460:53-59.
10. Wu G., Liu N., Rittelmeyer I., Sharma A.D., Sgodda M., Zaehres H., et al. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol 2011, 9:e1001099.
11. Yao S., Sukonnik T., Kean T., Bharadwaj R.R., Pasceri P., Ellis J. Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications. Mol Ther 2004, 10:27-36.
12. Minoguchi S., Iba H. Instability of retroviral DNA methylation in embryonic stem cells. Stem Cells 2008, 26:1166-1173.
13. Herbst F., Ball C.R., Tuorto F., Nowrouzi A., Wang W., Zavidij O., et al. Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation invivo. Mol Ther 2012, 20:1014-1021.
14. Hotta A., Ellis J. Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. JCell Biochem 2008, 105:940-948.
15. Schlesinger S., Lee A.H., Wang G.Z., Green L., Goff S.P. Proviral silencing in embryonic cells is regulated by yin yang 1. Cell Rep 2013, 4:50-58.
16. Wolf D., Goff S.P. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 2007, 131:46-57.
17. Wolf D., Goff S.P. Embryonic stem cells use ZFP809 to silence retroviral DNAs. Nature 2009, 458:1201-1204.
18. Antoniou M.N., Skipper K.A., Anakok O. Optimizing retroviral gene expression for effective therapies. Hum Gene Ther 2013, 24:363-374.
19. Grez M., Akgun E., Hilberg F., Ostertag W. Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci U S A 1990, 87:9202-9206.
20. Schambach A., Zychlinski D., Ehrnstroem B., Baum C. Biosafety features of lentiviral vectors. Hum Gene Ther 2013, 24:132-142.
21. Schambach A., Moritz T. Toward position-independent retroviral vector expression in pluripotent stem cells. Mol Ther 2013, 21:1474-1477.
22. Emery D.W. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther 2011, 22:761-774.
23. Antoniou M., Harland L., Mustoe T., Williams S., Holdstock J., Yague E., et al. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 2003, 82:269-279.
24. Williams S., Mustoe T., Mulcahy T., Griffiths M., Simpson D., Antoniou M., et al. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol 2005, 5:17.
25. Zhang F., Frost A.R., Blundell M.P., Bales O., Antoniou M.N., Thrasher A.J. Aubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010, 18:1640-1649.
26. Zhang F., Thornhill S.I., Howe S.J., Ulaganathan M., Schambach A., Sinclair J., et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 2007, 110:1448-1457.
27. Pfaff N., Lachmann N., Ackermann M., Kohlscheen S., Brendel C., Maetzig T., et al. Aubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells 2013, 31:488-499.
28. Lachmann N., Jagielska J., Heckl D., Brennig S., Pfaff N., Maetzig T., et al. MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapy. Gene Ther 2012, 19:915-924.
29. Pfaff N., Lachmann N., Kohlscheen S., Sgodda M., Arauzo-Bravo M.J., Greber B., et al. Efficient hematopoietic redifferentiation of induced pluripotent stem cells derived from primitive murine bone marrow cells. Stem Cells Dev 2012, 21:689-701.
30. Eggenschwiler R., Loya K., Wu G., Sharma A.D., Sgodda M., Zychlinski D., et al. Sustained knockdown of a disease-causing gene in patient-specific induced pluripotent stem cells using lentiviral vector-based gene therapy. Stem Cells Transl Med 2013, 2:641-654.
31. Eggenschwiler R., Loya K., Sgodda M., Andre F., Cantz T. Hepatic differentiation of murine disease-specific induced pluripotent stem cells allows disease modelling invitro. Stem Cells Int 2011, 2011:924782.
32. Warlich E., Kuehle J., Cantz T., Brugman M.H., Maetzig T., Galla M., et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther 2011, 19:782-789.
33. van Wilgenburg B., Browne C., Vowles J., Cowley S.A. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS One 2013, 8:e71098.
34. Xu X.Q., Soo S.Y., Sun W., Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 2009, 27:2163-2174.
35. Hartung S., Schwanke K., Haase A., David R., Franz W.M., Martin U., et al. Directing cardiomyogenic differentiation of human pluripotent stem cells by plasmid-based transient overexpression of cardiac transcription factors. Stem Cells Dev 2013, 22:1112-1125.
36. Xu X.Q., Graichen R., Soo S.Y., Balakrishnan T., Rahmat S.N., Sieh S., et al. Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation 2008, 76:958-970.
37. Lachmann N., Brennig S., Pfaff N., Schermeier H., Dahlmann J., Phaltane R., et al. Efficient invivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector system. Gene Ther 2013, 20:298-307.
38. Bock C., Reither S., Mikeska T., Paulsen M., Walter J., Lengauer T. BiQ analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005, 21:4067-4068.
39. Schlegelberger B., Metzke S., Harder S., Zühlke-Jenisch R., Zhang Y., Siebert R. Classical and molecular cytogenetics of tumor cells. Diagnostic cytogenetics. XIV 1999, Springer. R.-D. Wegner (Ed.).
40. Pfaffl M.W. Anew mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
41. Pfaff N., Fiedler J., Holzmann A., Schambach A., Moritz T., Cantz T., et al. miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. EMBO Rep 2011, 12:1153-1159.
42. Dijkstra D., Hennig C., Witte T., Hansen G. Basophils from humans with systemic lupus erythematosus do not express MHC-II. Nat Med 2012, 18:488-489. author reply 9-90.
43. Wang T., Wu H., Li Y., Szulwach K.E., Lin L., Li X., et al. Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency. Nat Cell Biol 2013, 15:700-711.
44. Bock C., Kiskinis E., Verstappen G., Gu H., Boulting G., Smith Z.D., et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011, 144:439-452.
45. Voelkel C., Galla M., Maetzig T., Warlich E., Kuehle J., Zychlinski D., et al. Protein transduction from retroviral gag precursors. Proc Natl Acad Sci U S A 2010, 107:7805-7810.
46. Hong S., Hwang D.Y., Yoon S., Isacson O., Ramezani A., Hawley R.G., et al. Functional analysis of various promoters in lentiviral vectors at different stages of invitro differentiation of mouse embryonic stem cells. Mol Ther 2007, 15:1630-1639.
47. Demaison C., Parsley K., Brouns G., Scherr M., Battmer K., Kinnon C., et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002, 13:803-813.
48. Brendel C., Muller-Kuller U., Schultze-Strasser S., Stein S., Chen-Wichmann L., Krattenmacher A., et al. Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 2012, 19:1018-1029.
49. Brennig S., Rattmann I., Lachmann N., Schambach A., Williams D.A., Moritz T. Invivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application. Cytotherapy 2012, 14:451-460.
50. Rattmann I., Kleff V., Sorg U.R., Bardenheuer W., Brueckner A., Hilger R.A., et al. Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an invivo murine transplant model. Blood 2006, 108:2965-2971.
51. Knight S., Zhang F., Mueller-Kuller U., Bokhoven M., Gupta A., Broughton T., et al. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. JVirol 2012, 86:9088-9095.
52. Stein S., Ott M.G., Schultze-Strasser S., Jauch A., Burwinkel B., Kinner A., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16:198-204.
53. Hockemeyer D., Soldner F., Beard C., Gao Q., Mitalipova M., DeKelver R.C., et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009, 27:851-857.
54. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., et al. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826.
55. Mussolino C., Morbitzer R., Lutge F., Dannemann N., Lahaye T., Cathomen T. Anovel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 2011, 39:9283-9293.
56. Bandaranayake A.D., Correnti C., Ryu B.Y., Brault M., Strong R.K., Rawlings D.J. Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. Nucleic Acids Res 2011, 39:e143.
57. Rival-Gervier S., Lo M.Y., Khattak S., Pasceri P., Lorincz M.C., Ellis J. Kinetics and epigenetics of retroviral silencing in mouse embryonic stem cells defined by deletion of the D4Z4 element. Mol Ther 2013, 21:1536-1550.